Golde, Todd E.
Funding for this research was provided by:
National Institute on Aging (P30AG066506, U01AG046139, RF1AG057933, RF1AG064942, RF1AG064914)
Article History
Received: 6 January 2022
Accepted: 17 February 2022
First Online: 5 March 2022
Declarations
:
: Not applicable.
: Not applicable.
: TEG is a co-founder of Lacerta Therapeutics Inc and Andante Biologics Inc. He has served on advisory boards for Eli Lilly, BMS, Novartis, Abbvie, Lundbeck, Pfizer, and Promis Neurosciences Inc. Dr. Golde is an associate editor of Molecular neurodegeneration.